Intended for healthcare professionals

News

Half of trials supporting new cancer drug approval in Europe had high risk of bias

BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l5619 (Published 19 September 2019) Cite this as: BMJ 2019;366:l5619

Linked Research

Design characteristics, risk of bias, and reporting of RCTs supporting approvals of cancer drugs by EMA

Please note that it may take up to 5 days for the peer review documents to appear.

For research papers The BMJ has fully open peer review. This means that accepted research papers published from early 2015 onwards usually have their prepublication history posted alongside them on bmj.com.

This prepublication history comprises all previous versions of the manuscript, the study protocol (submitting the protocol is mandatory for all clinical trials and encouraged for all other studies at The BMJ), the report from the manuscript committee meeting, the reviewers’ comments, and the authors’ responses to all the comments from reviewers and editors.

In rare instances we determine after careful consideration that we should not make certain portions of the prepublication record publicly available. For example, in cases of stigmatised illnesses we seek to protect the confidentiality of reviewers who have these illnesses. In other instances there may be legal or regulatory considerations that make it inadvisable or impermissible to make available certain parts of the prepublication record.

In all instances in which we have determined that elements of the prepublication record should not be made publicly available, we expect that authors will respect these decisions and also will not share this information.